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Abstract
Background: S100B is a potential marker of neurological and psychiatric illness. In schizophrenia, increased S100B levels, as
well as associations with acute positive and persisting negative symptoms, have been reported. It remains unclear whether
S100B elevation, which possibly reflects glial dysfunction, is the consequence of disease or compensatory processes, or
whether it is an indicator of familial risk.
Methods: Serum samples were acquired from two large independent family samples (n = 348 and n= 254) in the
Netherlands comprising patients with psychotic disorder (n = 140 and n= 82), non-psychotic siblings of patients with
psychotic disorder (n = 125 and n= 94) and controls (n = 83 and n= 78). S100B was analyzed with a Liaison automated
chemiluminescence system. Associations between familial risk of psychotic disorder and S100B were examined.
Results: Results showed that S100B levels in patients (P) and siblings (S) were not significantly different from controls (C)
(dataset 1: P vs. C: B = 0.004, 95% CI 20.005 to 0.013, p = 0.351; S vs. C: B = 0.000, 95% CI 20.009 to 0.008, p = 0.926; and
dataset 2: P vs. C: B = 0.008, 95% CI 20.011 to 0.028, p = 0.410; S vs. C: B = 0.002, 95% CI 20.016 to 0.021, p = 0.797). In
patients, negative symptoms were positively associated with S100B (B = 0.001, 95% CI 0.000 to 0.002, p = 0.005) in one of the
datasets, however with failure of replication in the other. There was no significant association between S100B and positive
symptoms or present use or type of antipsychotic medication.
Conclusions: S100B is neither an intermediate phenotype, nor a trait marker for psychotic illness.
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Introduction
The search for biological markers and endophenotypes is
ongoing in the field of psychiatry. The term biomarker refers to a
characteristic that can be objectively measured and evaluated as
an indicator of normal and pathogenic biological processes [1].
Their identification may offer insight into etiological mechanisms
of disease and offer new treatment perspectives. In clinical
practice, valid biomarkers assist in the diagnostic process and
enable monitoring of disease course and treatment response [1,2].
S100B is a protein that has been described as a potential
biomarker of neurological and psychiatric disease. It has been
coined ‘‘the CRP (C-reactive protein) of the brain’’ [3], and is an
indicator of central nervous system (CNS) pathology from birth
until elderly age [4]. S100B is expressed in and secreted by glial
cells, with dual effects: at physiological intracellular levels and
nanomolar extracellular concentrations it is neurotrophic [5,6]; at
micromolar levels it becomes neurotoxic [3,5–7]. Elevated serum
S100B in schizophrenia has been fairly consistently reported since
the first publication more than a decade ago [8], and has been
confirmed by a meta-analysis [9]. This meta-analysis, however,
was not based on systematic review and did not report on
apparently high levels of heterogeneity. Also, studies included were
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typically very small and no analysis of possible publication bias was
provided. A few studies reported absence of association or
inconclusive findings [10–12].
Initially, S100B elevation was ascribed to glial dysfunction or
astrocytic activation [13,14]. It is not understood whether it results
from passive release secondary to neuronal damage, or active
secretion due to glial activation as a primary pathophysiological or
compensatory mechanism. Indirect evidence points to active
secretion illustrated by reports of isolated elevation of S100B
levels, unaccompanied by established markers of neuronal damage
[9,11]. In addition, increased S100B levels have been associated
with increased metabolism in glial cells measured by magnetic
resonance spectroscopy [15]. Clinically, elevated S100B may be
associated with acute psychosis and persistent negative symptoms
[10,16–18]. Histological findings indicate that glial activation may
result in increased intracellular S100B in paranoid schizophrenia
(positive symptoms), whereas white matter damage or dysfunction
in residual schizophrenia (negative symptoms) may lead to
extracellular release [19].
More recently, S100B in schizophrenia has been related to
glucose metabolism and insulin resistance [20]. Altered glucose
metabolism in schizophrenia is frequently associated with the use
of second-generation antipsychotics, but changes in insulin
resistance and insulin-related peptides have also been observed
in antipsychotic-naı¨ve patients [21,22], suggesting an etiologic role
for hyperinsulinemia. The two mechanisms may not be mutually
exclusive. Abnormal glucose metabolism (i.e. diabetes) leads to
small vessel disease, which causes white matter lesions. Accord-
ingly, glucose abnormalities may cause secondary glial dysfunc-
tion, with or without primary altered glial function.
Notably, both white matter irregularities [23–26] and glucose
abnormalities [27–29] have been reported in unaffected first-
degree relatives of patients with schizophrenia. However, it is not
known whether S100B changes exist in this group. Two Chinese
studies have investigated S100B gene polymorphisms as possible
indicators of susceptibility to schizophrenia. The first study [30]
found that the V3–V4 (G-C) haplotype of the S100B gene was
more prevalent in patients than controls, whereas the second study
[31] reported an absence of significant differences in genotypes or
allele frequencies of S100B gene polymorphisms between patients
and controls.
In summary, it remains unclear whether S100B elevation is
associated with schizophrenia, and if so, whether the association
reflects the consequence of acute or chronic disease processes,
compensatory mechanisms or genetic risk for schizophrenia. We
set out to test whether S100B levels are associated with (familial
risk of) psychotic disorder, in two large and independent samples.
We hypothesized that S100B levels would be elevated in both
siblings and patients, suggesting that S100B elevation may be
considered an intermediate phenotype.
Materials and Methods
Subjects
Data was collected in the context of an ongoing longitudinal
multicentre study in the Netherlands [32,33]. The present total
study population comprised cross-sectional data from two large
independent samples derived from: i) Amsterdam and Rotterdam,
including surrounding areas, and ii) Maastricht and surrounding
areas (extending into nearby Belgium) (hereafter referred to as the
Amsterdam and Maastricht samples respectively). Patients with a
minimum age of 16 years with a diagnosis of non-affective
psychotic disorder were included. Patients were recruited through
the mental health services where they were treated, either as in or
outpatients. Diagnosis was based on DSM-IV criteria [34],
assessed with the Comprehensive Assessment of Symptoms and
History (CASH) interview [35]. Siblings were sampled through
participating patients. On a few occasions, the patient refused
participation but the sibling wished to participate, in which case
the sibling was included independently. The CASH was also used
to confirm the absence of a diagnosis of non-affective psychosis in
the siblings, and absence of lifetime diagnosis of psychotic disorder
in the control subjects. Control subjects were recruited using
random mailings in nearby municipalities and through advertise-
ment in newspapers. For the control subjects, the occurrence of
any psychotic disorder in either the subject or any first-degree
family member, assessed using the Family Interview for Genetic
Studies, constituted an exclusion criterion.
Additional exclusion criteria constituted oncologic processes,
autoimmune disease, current infectious disease, cardiovascular
disease and neurological disease.
Amsterdam sample. The Amsterdam sample comprised
140 patients, 125 non-psychotic siblings and 83 controls. Patients
in this sample were diagnosed with schizophrenia (n = 89),
schizophreniform disorder (n = 6), schizoaffective disorder
(n = 19), delusional disorder (n = 1), substance-induced psychotic
disorder (n = 2), brief psychotic disorder (n = 1) and psychotic
disorder NOS (n = 22). There were 10 siblings with a diagnosis of
major depressive disorder (MDD), two siblings with bipolar
disorder, two siblings with developmental disorders and one
sibling with anorexia nervosa. Among the controls, 3 were
diagnosed with MDD and one with dysthymic disorder. Ninety
families from the Amsterdam area participated. Sixty-three
families contributed one patient and one sibling, 20 families
contributed one patient and two siblings, three families contrib-
uted one patient and three siblings and one family contributed one
patient and four siblings. Two families contributed two siblings,
but no patients. One family contributed two controls. Fifty-three
independent patients, 5 independent siblings and 81 independent
controls participated, i.e. these individuals had no relatives in the
sample.
Maastricht sample. The Maastricht sample consisted of 82
patients with psychotic disorder, 94 non-psychotic siblings of
patients, and 78 controls. Of the patients, 59 were diagnosed with
schizophrenia and 16 were diagnosed with schizoaffective
disorder, 2 had a substance-induced psychotic disorder and 1
patient was diagnosed with brief psychotic disorder. The other
patients (n = 4) were diagnosed with psychotic disorder not
otherwise specified (NOS). In addition, 28 siblings and 16 controls
had a diagnosis of MDD. A total of 50 families from Maastricht
participated in the study. Thirty-one families contributed one
patient and one sibling, seven families contributed one patient and
two siblings, one family contributed one patient and three siblings
and one family contributed two patients but no siblings. Four
families contributed two siblings and one family contributed three
siblings, but no patients. Five families contributed two controls.
Forty-one independent patients, 35 independent siblings and 68
independent controls participated.
Measures
Body mass index (BMI). BMI was calculated as weight in
kilograms divided by height in meters squared.
Positive and negative symptoms. Psychotic symptomatol-
ogy was assessed with the Positive and Negative Syndrome Scale
(PANSS) [36]. The scores of the individual items of the positive
and negative symptom dimensions were summed.
Antipsychotic medication. Self-report present use and type
of antipsychotic medication (AP) was documented. AP was
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categorized by generation, i.e. first generation antipsychotics
(FGA) or second and third generation antipsychotics (SGA and
TGA respectively). For the analyses, SGA and TGA were
combined. In case of simultaneous use of an FGA and SGA or
TGA, the AP type was classified as FGA.
Serum sample acquisition and processing
Serum samples were acquired by venipuncture and were
centrifuged and frozen within 24 hours. S100B was analyzed
using a Liaison automated chemiluminescence analyzer according
to the manufacturer’s instructions (Diasorin). The lowest concen-
tration of detection was 0.02 microgram per liter. ROC curves
showed best accuracy for the Liaison Sangtec 100 assay [37]. All
samples (from both locations) were analyzed at the same
laboratory of the Radboud University Medical Centre, employing
the same technique.
Ethics statement
This study was approved by the standing ethics committees of
the University Medical Centres of Utrecht (G.R.O.U.P. study),
Amsterdam, Rotterdam and Maastricht. All subjects provided
written informed consent in accordance with the committee’s
guidelines.
Statistical analysis
The strategy was analysis in one sample followed by within-
study replication in the other sample. Per sample, group
differences in S100B were analyzed using multilevel random
regression models because of hierarchical clustering occasioned by
the fact that participants were clustered in families, compromising
statistical independence of the observations [38]. This was done
using the XTREG command in STATA (STATA corp, version
11). S100B was the dependent variable in the analyses and group
(entered as both linear and dummy variables (controls = 0,
siblings = 1 and patients = 2)) was the independent variable.
Analyses were adjusted for the following a priori hypothesized
confounders: sex, age and BMI. In addition, we tested whether
S100B was not only conditional on group but also on sex, by
examining group6sex interactions corrected for age and BMI.
Interactions terms were evaluated by Wald test [39].
To account for the clinical heterogeneity in the patient samples,
the association between group and S100B was examined in two
subgroups: i) patients with a narrowly defined diagnosis of
schizophrenia (i.e. excluding schizoaffective disorder, schizophren-
iform disorder, delusional disorder and psychotic disorder NOS),
and ii) patients with any psychotic disorder with PANSS positive
and negative scores of fifteen or higher.
As S100B may be elevated in mood disorders [40], sensitivity
analyses were conducted, excluding controls and siblings with a
history of affective disorders or other psychiatric morbidity.
Associations between the PANSS symptom levels and S100B
were investigated in the patient samples using multilevel regression
analyses for the Maastricht sample (given hierarchical clustering of
patients within families) and multiple regression analyses for the
Amsterdam sample, with S100B as the dependent variable and
symptom scores as the independent variable. In order to visualize
dose-response in case of an association, PANSS symptoms scores
were entered as dummy variables representing the distribution of
the scores divided by its tertiles. Analyses were corrected for sex
and age.
Multilevel (Maastricht sample) and multiple regression proce-
dures (Amsterdam sample) were also used to investigate associa-
tions between present use of AP (0 = no current use, 1 = current
use) and S100B. Associations between type of AP and S100B were
examined by comparing FGA and SGA/TGA to no AP (0 = no
AP, 1 = FGA, 2 = SGA/TGA). AP analyses were corrected for sex,
age and BMI.
Results
Descriptive analyses
Eighty-six percent of the Amsterdam patients and 77% of the
Maastricht patients was male; for the control group these figures
were 69% and 32% respectively. The mean age and BMI of all
groups was higher in the Maastricht sample. Patients from
Amsterdam had higher negative symptom levels than those from
Maastricht. Symptom levels in siblings and controls were not
reported because of the high proportion of missing values in the
Amsterdam sample (Table 1).
Within the samples, patients and siblings were younger than
controls in Maastricht while siblings were older than patients in
Amsterdam. In Maastricht, BMI was higher in patients compared
to controls, but not siblings. Patients from Amsterdam had a
higher BMI compared to both controls and siblings (Table 1).
Out of 140 patients from the Amsterdam sample, 112 reported
the present use of an AP. Thirty-five patients used olanzapine, 31
used risperidone, 13 used clozapine, 8 used aripiprazole, 5
quetiapine, 5 haloperidol and 2 penfluridol. Two used flu-
penthixol, one used pimozide, and one sulpiride. Three individuals
Table 1. Demographic characteristics.
Controls Siblings Patients
Number of participants
Amsterdam 83 125 140
Maastricht 78 94 82
Sex (male/female)
Amsterdam 57/26 57/68 120/20
Maastricht 25/53 44/50 63/19
S100B (mg/l)
Amsterdam 0.07060.028 0.07060.029 0.07560.033
Maastricht 0.07660.028 0.07860.039 0.08360.078
Age
Amsterdam 26.1669.31 27.0368.11 24.6566.00
Maastricht 34.40610.39 31.6168.59 30.5066.93
BMI (kg/m2)
Amsterdam 22.4162.47 22.9463.37 23.8863.69
Maastricht 24.3964.74 24.8064.56 25.9664.13
Positive symptoms
(PANSS)
Amsterdam 12.0065.18
Maatricht 11.5065.25
Negative symptoms
(PANSS)
Amsterdam 16.2166.83
Maastricht 11.1764.66
Present use of AP (yes/no)
Amsterdam 112/13 (15 NA)
Maastricht 72/10
Means 6 standard deviations reported. PANSS: Positive and negative syndrome
scale; NA: not available.
doi:10.1371/journal.pone.0082535.t001
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used a combination of haloperidol and clozapine, 2 used
risperidone and quetiapine, 1 a combination of aripiprazole and
olanzapine and 1 person used pimozide and risperidone. Two
patients were unable to provide the name of the current AP. For
fifteen patients, AP data was missing.
In the Maastricht sample, 72 out of 82 patients currently used
AP medication. Sixteen patients used risperidone, 16 used
olanzapine, 12 used aripiprazole, 7 used clozapine, 5 quetiapine,
3 haloperidol and 2 used amisulpride. Two patients used
zuclopenthixol and bromperidol, respectively. Two persons used
a combination of clozapine and aripiprazole, 1 a combination of
aripiprazole and olanzapine, 1 haloperidol and pipamperone, 1
zuclopenthixol and quetiapine, 1 clozapine and clotiapine, 1
risperidone and aripiprazole, 1 risperidone and paliperidone, and
1 a combination of risperidone, amisulpride and clotiapine. One
sibling with a diagnosis of depression used a low dose of
olanzapine.
Associations between group and S100B
Although the direction of the effect was positive, there was no
significant association between group (linear trend) and S100B in
the samples (Amsterdam: B = 0.002, 95% CI 20.002 to 0.006,
p = 0.377; and Maastricht: B = 0.004, 95% CI 20.006 to 0.014,
p = 0.407).
Between group (dummy variable) comparisons showed that
S100B levels in patients and siblings were not significantly different
from controls (Amsterdam: P vs. C: B = 0.004, 95% CI 20.005 to
0.013, p = 0.351; S vs. C: B = 0.000, 95% CI 20.009 to 0.008,
p = 0.926; and Maastricht: P vs. C: B = 0.008, 95% CI 20.011 to
0.028, p = 0.410; S vs. C: B = 0.002, 95% CI 20.016 to 0.021,
p = 0.797), nor was there a large or significant difference between
patients and siblings (Table 2).
Association between group and S100B: subgroup
analyses
Narrow schizophrenia diagnosis only. Excluding patients
with a diagnosis other than schizophrenia altered the pattern of
effect sizes in some instances, but none of the between-group
comparisons was statistically significant (Table 2), nor the effect of
group as a linear trend variable (Amsterdam: B = 0.001, 95% CI
20.004 to 0.006, p = 0.696; and Maastricht: B = 0.001, 95% CI
20.008 to 0.010, p = 0.806).
All psychotic disorders with PANSS scores $15 (on
positive and negative subscales respectively). At a cut-off
of fifteen in PANSS positive symptom levels, 33 patients remained
in the Amsterdam sample and 14 remained in the Maastricht
sample. There were no significant associations between S100B and
group (linear trend) (Amsterdam: B = 0.002, 95% CI 20.004 to
0.008, p = 0.539; and Maastricht: B = 0.000, 95% CI 20.010 to
0.010, p = 0.966). In the between-group comparison, patients had
significantly higher S100B levels compared to siblings in the
Amsterdam sample, although patients and siblings were not
significantly different from controls. In the Maastricht sample,
there were no large or significant associations between group and
S100B, with an opposite direction of effect sizes (Table 2).
At a cut-off of fifteen in PANSS negative symptom levels, 72
Amsterdam and 13 Maastricht patients remained in the analyses.
There was no significant association between S100B and group as
a linear trend variable (Amsterdam: B = 0.005, 95% CI 0.000 to
0.010, p = 0.076; and Maastricht: B = 0.005, 95% CI 20.005 to
0.015, p = 0.349). However, between-group comparisons showed
that patients in Amsterdam had significantly higher S100B levels
than siblings (B = 0.011, 95% CI 0.002 to 0.020, p = 0.016), and
controls - at trend-level (B = 0.010, 95% CI 0.000 to 0.020,
p = 0.051). This was not replicated in the Maastricht sample
(Table 2).
Table 2. Associations between group and S100B.
S vs. C P vs. C P vs. S
B (95% CI), p-value B (95% CI), p-value B (95% CI), p-value
Group (AD +)
Amsterdam 0.000 (20.009–0.008), p = 0.926 0.004 (20.005–0.013), p = 0.351 0.005 (20.003–0.012), p = 0.207
Maastricht 0.002 (20.016–0.021), p = 0.797 0.008 (20.011–0.028), p = 0.410 0.006 (20.011–0.023), p = 0.504
Group (AD 2)
Amsterdam 0.000 (20.009–0.009), p = 0.995 0.004 (20.005–0.013), p = 0.396 0.004 (20.003–0.011), p = 0.254
Maastricht 0.001 (20.020–0.023), p = 0.897 0.009 (20.013–0.030), p = 0.436 0.007 (20.013–0.027), p = 0.482
Group (SCZ only)
Amsterdam 20.001 (20.010–0.008), p = 0.821 0.003 (20.006–0.013), p = 0.473 0.004 (20.003–0.012), p = 0.268
Maastricht 0.001 (20.014–0.016), p = 0.875 20.001 (20.019–0.017), p = 0.926 20.002 (20.017–0.013), p = 0.787
Group (PANSS pos$15)
Amsterdam 20.002 (20.011–0.006), p = 0.598 0.008 (20.003–0.020), p = 0.165 0.010 (0.000–0.020), p = 0.040
Maastricht 0.003 (20.010–0.015), p = 0.702 20.005 (20.026–0.017), p = 0.683 20.007 (20.027–0.013), p = 0.487
Group (PANSS neg$15)
Amsterdam 20.001 (20.010–0.008), p = 0.850 0.010 (0.000–0.020), p = 0.051 0.011 (0.002–0.020), p = 0.016
Maastricht 0.002 (20.011–0.015), p = 0.719 0.011 (20.012–0.034), p = 0.344 0.009 (20.012–0.029), p = 0.410
B represents the regression coefficient of the multilevel regression analyses. 95% CI: 95% confidence interval.
S vs. C: sibling versus control; P vs. C: patient versus control; P vs. S: patient versus sibling.
AD +: affective disorders in controls and siblings included; AD 2: affective disorders in controls and siblings excluded; SCZ: schizophrenia only in patient groups; PANSS:
Positive and negative syndrome scale; PANSS pos$15: PANSS positive symptom level above or equal to 15 in patient groups; PANSS neg$15: PANSS negative symptom
level above or equal to 15 in patient groups.
doi:10.1371/journal.pone.0082535.t002
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Exclusion of affective disorders and other psychiatric
morbidity in siblings and controls. The exclusion of controls
and siblings with a history of affective disorder or other psychiatric
morbidity did not affect the findings when using the original
patient samples, or any of the above described sub-analyses
(Table 2).
Associations between symptomatology and S100B
In patients (all diagnoses), negative symptoms were positively
associated with S100B in the Amsterdam sample (B = 0.001, 95%
CI 0.000 to 0.002, p = 0.005), but not in the Maastricht sample
(B = 0.002, 95% CI 20.002 to 0.005, p = 0.308). In the
Amsterdam sample, progressively higher negative symptom levels
were associated with progressively higher S100B levels, although
only the highest negative symptom level reached statistical
significance (high vs. low symptom group: B = 0.016, 95% CI
0.003 to 0.030, p = 0.020; intermediate vs. low symptom group:
B = 0.010, 95% CI 20.003 to 0.024, p = 0.127).
There was no large or statistically significant association
between positive symptoms and S100B in the Amsterdam or
Maastricht sample (B = 0.001, 95% CI 0.000 to 0.002, p = 0.098;
and B =20.001, 95% CI20.004 to 0.002, p = 0.483 respectively).
Associations between antipsychotic medication and
S100B
In patients, the present use of AP medication was not
significantly associated with S100B (Amsterdam: B =20.003,
95% CI 20.022 to 0.017, p = 0.781; Maastricht: B = 0.027, 95%
CI 20.024 to 0.078, p = 0.302). Similarly, there was no effect of
type of AP, comparing FGA and SGA/TGA users to AP-free
patients and comparing FGA to SGA/TGA users (Table 3).
Group6sex interactions and S100B
There was no evidence for significant group6sex interactions in
either sample (Amsterdam: x2 = 0.35, p = 0.839; Maastricht:
x2 = 1.45, p = 0.484).
Discussion
Contrary to the hypothesis, there was no statistically significant
association between group and S100B. Serum S100B levels in
patients and siblings were not different from controls. In the
Amsterdam sample, there was a significant positive association
between negative symptoms and S100B, which was not replicated
in the Maastricht sample. There was no large or significant
association between S100B and positive symptoms or the present
use or type of AP in either sample.
Findings
(Familial) risk of psychotic disorder and S100B. We did
not detect significantly elevated S100B in patients, in disagreement
with a range of previous small studies. Other investigations
suggesting an absence of elevated S100B in schizophrenia are
limited. One study found unaltered S100B levels in unmedicated
patients compared to controls, although S100B was elevated in
patients who had been treated with AP for 3 weeks compared to
unmedicated patients and controls [10]. In another study, a small
sample of patients with schizophrenia had higher levels of S100B
in cerebrospinal fluid (CSF) but not serum (after Bonferroni
correction) [11]. There is one study reporting reduced S100B
levels [12]. Although the absence of elevated S100B in patients
does not agree with most literature, the current results provided a
replication in two samples that were considerably larger than
earlier work (except for two studies [18,41]). Another difference
between the current and other studies concerns the patient
population. The current samples comprised mainly outpatients,
generally not in an acute stage of the disorder, with a mean illness
duration of ,10 years, whereas the majority of previous work was
conducted in hospitalized patients. The evidence to date may thus
be suggestive of S100B elevation in inpatient populations with
presumably more severe symptomatology. Furthermore, a consid-
erable proportion of the patients in the current study had a
psychotic disorder other than schizophrenia, while previous studies
were conducted specifically in schizophrenic patients. However,
the diagnosis of schizophrenia does not refer to a natural illness
type. The different diagnostic categories in the DSM-IV chapter of
psychotic disorders likely reflect phenotypic diversity related to a
shared liability. In addition, the sensitivity analyses (excluding
patients with a diagnosis of psychotic disorder other than
schizophrenia) did not provide evidence for differences between
groups. It should further be noted that serological and histological
S100B alterations have been associated with affective disorders
[40,42]. In the current sample in- or exclusion of all psychiatric
morbidity in siblings and controls yielded the same results: the
absence of association between serum S100B and risk of psychotic
disorder.
This is the first study to investigate serum S100B as a marker of
familial risk of psychotic disorder. The use of non-psychotic
siblings in the study design makes it possible to establish the effect
of shared familial risk of psychotic disorder, without confounding
by disease-related factors. The data did not suggest that serum
S100B is an intermediate phenotype for psychotic disorder. The
absence of S100B alterations in our relatively stable patient and
non-psychotic sibling populations, in combination with the
previously reported increased S100B levels in hospitalized patient
populations, may suggest that S100B elevations reflect fluctuating
disease processes in certain patient populations, i.e. that they are
related to the clinical ‘‘state’’. This reasoning may be underscored
by the (albeit weak) association between S100B and negative
symptoms in the Amsterdam sample. Alternatively, it may be that
previous work reporting positive associations was influenced by
publication/reporting bias, particularly given the suggestion of
Table 3. Associations between AP medication and S100B.
FGA vs. no AP SGA/TGA vs. no AP SGA/TGA vs. FGA
Patients
Amsterdam 0.005 (20.020–0.029), p = 0.713 20.004 (20.024–0.015), p = 0.659 20.009 (20.028–0.010), p = 0.335
Maastricht 20.001 (20.076–0.073), p = 0.970 0.030 (20.021–0.081), p = 0.248 0.031 (20.029–0.092), p = 0.309
B (95% confidence interval) and p-value reported. B represents the regression coefficient of the regression analyses.
AP: antipsychotic medication; FGA: first generation AP; SGA/TGA: second and third generation AP.
doi:10.1371/journal.pone.0082535.t003
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excess significance bias in the literature, affecting the representa-
tion of true associations between psychiatric phenotypes and
biological measures [43].
Symptomatology and S100B. Narrowing down the diagno-
sis of schizophrenia did not affect the pattern of findings. In
addition, patients in the Amsterdam sample with more severe
positive symptomatology (PANSS scores $15) had higher S100B
levels compared to siblings but not compared to controls, while
patients with more severe negative symptoms had higher S100B
levels compared to both siblings and controls (at trend-level),
regardless of diagnosis. This was not replicated in the Maastricht
sample. A cut-off of 15 for the PANSS positive and negative
symptom levels is clinically quite conservative. A higher cut-off,
however, would have further reduced the samples size. These
findings suggest that the absence of S100B elevation was not due
to diagnostic heterogeneity.
To examine whether S100B elevation may be associated with
higher symptom levels in patient populations, main effects of
symptomatology on S100B were assessed. The positive association
between negative symptoms and S100B, as found in the
Amsterdam sample, has been reported previously [10,13,16,17].
Despite the statistical significance of this finding, the clinical
relevance is debatable given the small effect size. Furthermore, the
association between negative symptoms and S100B levels was not
replicated in the Maastricht sample, although size and direction of
the association were similar. Patients in Amsterdam had higher
negative symptom levels than patients in Maastricht, possibly due
to the higher proportion of men in the Amsterdam sample. The
negative symptom level in the Maastricht patient sample was also
quite low compared to other studies that did find an association
using the PANSS.
A recent review [44] expressed the opinion that S100B studies
have been tainted by bias due to selection of patients with high
negative symptom levels. Nevertheless, certain explanations for a
true positive association between S100B and negative symptoms
could be conceived. First, neuroimaging work [45] has confirmed
white matter tracts as sites of profuse S100B expression (by glia
and oligodendrocytes) and white matter abnormalities have been
associated with negative symptoms [46–50]. Second, S100B may
reflect a compensatory mechanism instead of a causative process,
cueing in recovery at a stage of illness when positive symptoms
have begun to remit and negative symptoms become more
prominent.
AP medication and S100B. Previously reported effects of AP
on S100B have been inconsistent. A decline in S100B after several
weeks of AP treatment has been reported [10,17], and in vitro
work by Steiner [51] also suggests that S100B levels are
normalized by AP. However, a longitudinal study showed that
S100B remained increased after 24 weeks of treatment [18]. In
other studies, medication-free patients with schizophrenia had
higher serum S100B than healthy controls [52] and drug-naı¨ve
first-episode patients had significantly higher serum S100B levels
than chronic patients on long-term AP [41], with the latter group
showing S100B elevation compared to healthy controls. These
studies show that S100B elevation cannot be ascribed to AP. A
recent meta-analysis did not find an association between S100B in
schizophrenia and AP treatment [9], in line with the current
findings.
Methodological considerations
The strength of the present study was that it comprised two
large patient-sibling-control samples, allowing for independent
replication. As an additional validation, we repeated the analyses
combining the Amsterdam and Maastricht samples to increase
power. In the combined sample, the absence of a significant
positive association between S100B and group was upheld. The
association between negative symptoms and S100B in patients
(which was only present in the Amsterdam sample) was not
significant (p = 0.081) in the combined sample (results available on
request).
Certain limitations should be addressed. There is debate about
the specificity of S100B as a marker of CNS pathology as S100B is
expressed in other cells and tissues in physiological circumstances,
e.g. adipocytes, chondrocytes, lymphocytes and melanocytes
[5,6,53], as well as in pathological conditions, e.g. cardiomyocytes
after infarction [5,6,54]. One way to circumvent this issue is to
obtain S100B levels in the CSF. In a comparative serum/CSF
study, serum S100B was found to mirror CSF concentrations [13].
Corroborating evidence comes from a study reporting that
extracerebral sources of S100B did not alter S100B serum levels
[55]. Thus, despite the diverse origins of serum S100B, evidence
suggests that serum S100B is correlated with CSF S100B.
As Steiner and colleagues found that S100B is associated with
BMI, we adjusted for BMI [53]. In contrast, Pham and colleagues
did not find an association between BMI and S100B [55]. The
pattern of our findings was unaltered when BMI was removed as a
covariate from the analysis. To clarify a potential link to insulin
resistance [20,56], it may be useful to measure HbA1c in future
studies.
Conclusions
Our findings suggest the following: i) S100B is not an
intermediate phenotype of psychotic disorder; and ii) S100B is
not elevated in the ‘‘general population’’ of individuals with
psychotic disorder.
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